The therapeutic efficacy of small molecule Trk inhibitors could also be enhanced if combined with cancer drugs that induce genotoxic-, oxidative- or ER-stress, which would be expected to augment tumour cell killing, upon inhibition of TrkAIII-dependent survival signaling. This evidence concerns the gene NTRK1 and neoplasm.